498 related articles for article (PubMed ID: 17163268)
1. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Wang XK; Zhang Y; Yang CM; Wang Y; Liu GY
Clin Drug Investig; 2006; 26(6):341-9. PubMed ID: 17163268
[TBL] [Abstract][Full Text] [Related]
2. [Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction].
Zhang Y; Wang XK; Yang CM; Liu GY
Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):81-4. PubMed ID: 14724106
[TBL] [Abstract][Full Text] [Related]
3. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S
Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
De Luca G; Marino P
Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
PRIME CARE Study Investigators Group
Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
[TBL] [Abstract][Full Text] [Related]
7. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
8. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
[TBL] [Abstract][Full Text] [Related]
9. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
Berkowitz SD; Stinnett S; Cohen M; Fromell GJ; Bigonzi F;
Am J Cardiol; 2001 Dec; 88(11):1230-4. PubMed ID: 11728348
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A
Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
Wallentin L; Goldstein P; Armstrong PW; Granger CB; Adgey AA; Arntz HR; Bogaerts K; Danays T; Lindahl B; Mäkijärvi M; Verheugt F; Van de Werf F
Circulation; 2003 Jul; 108(2):135-42. PubMed ID: 12847070
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials.
Singh S; Bahekar A; Molnar J; Khosla S; Arora R
Clin Cardiol; 2009 Jul; 32(7):358-64. PubMed ID: 19609890
[TBL] [Abstract][Full Text] [Related]
14. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
[TBL] [Abstract][Full Text] [Related]
15. [Deviation of activated partial thromboplastin time from optimal level after 12 hours of intravenous infusion of unfractionated heparin -- an independent predictor of recurrence and unfavorable 30-day prognosis in patients with myocardial infarction].
Shalaev SV; Shava VP; Petrik ES; Pushnikova MA; Zhuravleva TD
Kardiologiia; 2005; 45(10):27-30. PubMed ID: 16234765
[TBL] [Abstract][Full Text] [Related]
16. Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.
McKeage K; Keating GM
Drugs; 2008; 68(1):105-22. PubMed ID: 18081375
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
Magee KD; Sevcik W; Moher D; Rowe BH
Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Antman EM; McCabe CH; Gurfinkel EP; Turpie AG; Bernink PJ; Salein D; Bayes De Luna A; Fox K; Lablanche JM; Radley D; Premmereur J; Braunwald E
Circulation; 1999 Oct; 100(15):1593-601. PubMed ID: 10517729
[TBL] [Abstract][Full Text] [Related]
19. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Menon V; Harrington RA; Hochman JS; Cannon CP; Goodman SD; Wilcox RG; Schünemann HJ; Ohman EM
Chest; 2004 Sep; 126(3 Suppl):549S-575S. PubMed ID: 15383484
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
